EliteG Infinite Compound Project

[moneytalks820]

GLIF has not had 3 positive days in a row before!!!This could be a first!

[eliteG]

end of the month on Halloween Monday... and into nice November.  Good Trading everybody, here is an update:

DCEL - movin down after hours.. so that was a good sell.. and would have made a good short   

DIAAF - closed nice.. lets see if anybody picks it up on their radar tonight   

GLIF - moved higher.. looks like thats the path of least resistance, would like some volume to make that clearer 

[jorgegr]

Let's hope GLIF.OB picks up some volume tomorrow. I'm still  in with 263000 shares.

jorgegr

[MarketMakerz]

For those of you candlestick junkies..here is the analysis of the recent activity on GLIF.
Today a Long White Candlestick was formed. Long white candle stick combined with long white doji from past 2 trading days is a buy signal confirmation.

Ofcourse we had our buy signal on GLIF waaaaay before. But today candlestick gave us our BUY CONFIRMED signal.

As EliteG said we need volume but watch the volume build up gradually.

We are that much closer to my prediction of $0.25 in 30 days.

GLIFFIN ALRIGHT!!!! HEADS UP!!! AWAY WE GO!!!

[OneStockMind]

I have to ask you Market what is your .25 prediction based on?

[jorgegr]

Is the 0.25 for GLIF.OB  based on TA or just a guesstimate 

jorgegr

[MarketMakerz]

Me?... Guesstimate?! Nah...Never!

It's based on the approximate market cap size for a small cap pharma company with a proven product(as soon as the news regarding cash inflow comes in) and potential to be the next target for a buyout by Merck.

None of you on this site probably know about the research that Merck is doing on cervical cancer. They happen to be looking for a cure for this cancer and we happen to hold on to the best testing method for such cancer.

It just so happen that technical analysis supports my view.

[MarketMakerz]

I post this interview with the CEO again for those who missed it the first tme i posted it here (interview was carried out in March of 2005. It could be used to give you a better picture of this company).
_______________________________________
BIO:
Stan Yakatan, MBA, is Chairman and CEO of Grant Life Sciences, Inc.  He has over 30 years experience as a chief executive, entrepreneur, and operational manager for biotech and medical companies.  He served as an executive and in several instances as CEO with New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific and Biosearch.   He has founded or co-founded more than 15 companies in the United States, Canada, Israel, France and Germany and in many cases served as the initial CEO, and Chairman of these companies. He sits on the board of directors of several public and private companies, and has served as an advisor to a number of the world's leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA) and Biocapital (Canada) as well as to the governments of Australia and Canada.

Company Profile:
Grant Life Sciences, Inc. develops products to improve the efficiency of diagnosing cervical cancer. The Company is developing protein-based screening tests to screen woman for cervical cancer and pre-cancerous conditions. These screening tests analyze blood for the presence of certain antibodies that appear only when cervical cancer or certain pre-cancerous conditions are present. Invasive cervical cancer kills approximately 300,000 women annually world-wide. There are more than 120 million cervical screening tests administered annually in the United States and Europe. But more than 120 million eligible women 20+ years old in developed nations still do not get Pap smears. Globally, more than 1.7 billion women over the age of 20 do not undergo any cervical cancer screening.

Question: Mr. Yakatan, please give us a little background on Grant Life Sciences.
Mr. Yakatan: "The technology behind Grant was begun over two years ago when a scientist from China, working with the University of Utah, teamed up with Dr. Mark Rosenfeld to do some work in cervical cancer. As a result of their initial activities they filed a patent for the use of various amino acids to identify the antibodies that surface when a woman has cervical cancer. They looked at blood and body fluids as opposed to the traditional Pap smear. With their patent applied for, they connected with a local entrepreneur named Michael Ahlin, who today is our Vice President of Development and a Director with Grant, and he provided some initial capital. When the venture capital route proved to be too dilutive, they began working with a brokerage firm here in New York to facilitate a reverse merger with a publicly traded entity to raise capital, which was done quickly and successfully. Then I and several others with a lot of experience were recruited to be the management team, which is where we are today."


Question: What is it that your test can do that others can't?
Mr. Yakatan: "Normally to check cervical cancer, women generally go for a Pap smear, which is considered in the industry to be highly inaccurate. Currently, there is no simple test, where you can just take the blood from a patient and determine by measuring antibodies in the blood whether cervical cancer or cervical cancer pre-cursors are present.  We have developed what we believe is the first blood test that does this, and the initial data is extremely compelling."


Question: What is it that your scientists have discovered that hasn't been done before?
Mr. Yakatan: "We've discovered in the literature five or six attempts to identify precursors to cervical cancer through various methods. What our group did is developed a series of oncogenic amino acid sequences.  We have characterized them in a way that can be utilized in a standard screening test where the amino acid sequences would truly identify the presence of cervical cancer or cervical cancer pre-cursors in blood or bodily fluid samples.  I don't think it's any trick or black magic; I think that we've just been able to do a lot of laboratory work in terms of screening hundreds of different amino acid sequences. We have discovered that a test that we would make for the U.S. market may have a different sequence than a test that we would make for the Indian or Chinese markets because the makeup of the oncogenes that show cervical cancer activity vary in different geographical areas of the world. What we are doing now is working very closely with a partner, Allogen, which is a part of the Cleveland Clinic Foundation, in trying to characterize all of these amino acids. We think that within three to six months, we'll be able to have our initial characterization completed and a product essentially ready to go into clinical trials, both in the United States and in other places in the world."


Question: What's the process and about how long does it take?
Mr. Yakatan: "We think that the longest process for us is the amino acid characterization.  What we want to do is a sample collection before we go to any regulatory agency; we then test these samples from thousands of patients in what we call institutional review board programs. We have a few of them already set-up at USC, UCLA, Johns Hopkins and a local hospital in Utah. We've begun an active program to identify 4,000 samples within a six-month period to do the characterization program. So we think it may take two to three months to characterize the amino acids; another four to six months to do the sample collection and process those samples. Then we would begin a regulatory submission. If we are lucky, and I say lucky is the key word, we will be able to file a 510K with the US FDA (Food and Drug Administration) as an adjunct to Pap smears and that process could take three to six months. However, if we have to do a complete product disclosure process, it could take as much as eighteen months to two years. We believe that in the rest of the world we can get a swift approval of our rapid test. We think that once the nine months to a year of laboratory development time and amino acid characterization is completed, we could put a product on the market outside of the U.S. within a year."


Question: Where do you go from here?
Mr. Yakatan: "We're continuing to characterize the amino acid sequences to make sure that we have the right sequences. We are currently developing two products, the first of which is an ELISA (Enzyme Linked Immunosorbent Assay) test which we would file as an adjunct in the United States through the FDA.   The second is a rapid test-- a point-of-care test that would be low cost and could serve the more than 1.7 billion women outside of the United States and Europe who normally don't get any type of cervical screening.  This probably accounts for over half the world and can be due to religious or economic reasons or just some type of taboo where women don't feel comfortable getting a cervical exam from a physician."


Question: Is there a market for rapid test in the United States?
Mr. Yakatan: "The issue is how imbedded the Pap smear is in the U.S. and whether or not we would  be able to get the community to accept a blood test after 50 years of doing traditional Paps. In our early discussions with people in the marketplace as well as the FDA, it's been suggested to us that the best way to get a new cancer test approved is as an adjunct. So, we think that strategically it makes sense to develop an adjunct test for the U.S. market and develop an inexpensive rapid test for the global market."


Question: Do you have enough funding going forward?
Mr. Yakatan: "Our initial capitalization was through a reverse merger were we raised about $1.8 million total. We are now looking for another $3 to $5 million and we think that with that second round of financing, we should be able to complete all of the pre-market activities and get the products on the market."


Question: What is the market potential for your test?
Mr. Yakatan: "In the United States, there are 60 million women who receive routine Paps of some form. Out of that, about 20% get false positives or false negatives, which lead to about 9 million colposcopy procedures; of that, 7 million turn out to be negative. So, we want to focus on an adjunct test where we could reduce the number of colposcopies and save the American health care system over $1.5 billion annually, not to mention eliminating the unnecessary mental anguish some of the false negatives create for our mothers and daughters.  We think that the U.S. market alone is about 7 to 10 million tests annually at $25.00 to $30.00 a test.  As I said before, the world market outside of the U.S. consists of over 1.7 billion women that have never been screened. We think that for those women, we can develop a test that would cost under $5.00, which is our goal. Then, we would ultimately put that same test on the market in the United States. I was retired for many years from being a CEO in biotech and when the opportunity came to me to look at a novel patented technology that serves an unmet market of over 1.7 billion people, that was enough excitement to get me to come back to work again."


Question: Can you give us an idea of what you are up against in the medical community to gain acceptance for your new approach?
Mr. Yakatan: "The issue is that Dr. George Papanicolaou developed this test about 68 years ago.  If you talk to any medical pathologist they will tell you that this is an archaic test that is highly inaccurate. However, it has become well accepted in the community. It is completely reimbursed by the insurance community and if they get a false positive, the patient would then go for a colposcopy, another reimbursable procedure. Unfortunately false negatives are more problematic of course. Just to give an idea of how well entrenched the Pap smear is in the United States, there was a recent article in the N.Y. Times that pointed out that about 12% of the women receiving Pap smears have had hysterectomies. They don't even have a cervix any longer to take a Pap sample from!.  Our new medical director, David Bolick, MD, FCAP, MIAC, is one of the most well-known spokesmen in the world for the replacement of the Pap smear. It's one of the reasons we brought David into our fold and he will be speaking at meetings all around the United States on our technology."


Question: What about going directly to women and women's groups?
Mr. Yakatan: "We plan to do exactly that. One of our founders, Michael Ahlin, has been given the responsibility to look into women's groups around the United States and see if we can generate support. It is common knowledge among the medical community that the current process of the cervical examination a very negative and highly invasive experience."


Question: Could you address potential investors; what should they know about the background of the management and the company that would make them want to invest it Grant Life Sciences?
Mr. Yakatan: "We have a very experienced management team. I have 35 years of experience in the biotech world. There are people who consider me part of the old guard. I've run companies like this before and much of the investment community knows who I am and my track record. We have a CFO, John Wilson, who has a similar background and a strong financial pedigree. He was senior banker at Credit Suisse First Boston and prior to that, served as CFO for Hardee's Food Systems, Perrier USA and Bell Canada International.  John has served on numerous boards, both public and private. In many of these cases, he was their CFO and did tremendous things for them. We have someone who has 20 years experience in product development ready to join us. In diagnostics we are working with the man who actually developed the rapid test program for Hoffmann-La Roche in terms of developing our rapid test program. We are working directly with the cancer center in China and that's important because China has the highest incidence of cervical cancer in the world. There are approximately 100,000 deaths there a year because of the lack of screening and we are the only company that is working directly with the center.  One of our founders, and a continuing consultant to the Company, is a scientific advisor to the center in China and has about ten years experience in the Chinese market. We brought on as a consultant to the company a former high level executive at the National Cancer Institute and he is working with us in terms of government funding and grants.  We believe that within the next 2 to 3 months we will solidify a major relationship with an institute in the United States that has the largest W.H.O. grant in the world for this type of work. So, we think that the combination of the experience of the management team, plus the market size and viability of the market are excellent opportunities for investors."


Question: In closing, could you tell us how long do you anticipate it will take for acceptance?
Mr. Yakatan: "The acceptance will be very rapid. We've actually had discussions with the Gates Foundation and other organizations that specialize in finding funding for third world countries and we are just in the early stages of those discussions. In reality, the company as it exists now is essentially two months old. The management team has worked very closely with the founders to pull together all the work that has been done to date and that has been a harmonious relationship."

[agatto2]

Nice post M&M's    thanks for sharing the research with us. agatto

[la-onda]

I post this interview with the CEO again for those who missed it the first tme i posted it here (interview was carried out in March of 2005. It could be used to give you a better picture of this company).
_______________________________________
BIO:
Stan Yakatan, MBA, is Chairman and CEO of Grant Life Sciences, Inc.  He has over 30 years experience as a chief executive, entrepreneur, and operational manager for biotech and medical companies.  He served as an executive and in several instances as CEO with New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific and Biosearch.   He has founded or co-founded more than 15 companies in the United States, Canada, Israel, France and Germany and in many cases served as the initial CEO, and Chairman of these companies. He sits on the board of directors of several public and private companies, and has served as an advisor to a number of the world's leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA) and Biocapital (Canada) as well as to the governments of Australia and Canada.

Company Profile:
Grant Life Sciences, Inc. develops products to improve the efficiency of diagnosing cervical cancer. The Company is developing protein-based screening tests to screen woman for cervical cancer and pre-cancerous conditions. These screening tests analyze blood for the presence of certain antibodies that appear only when cervical cancer or certain pre-cancerous conditions are present. Invasive cervical cancer kills approximately 300,000 women annually world-wide. There are more than 120 million cervical screening tests administered annually in the United States and Europe. But more than 120 million eligible women 20+ years old in developed nations still do not get Pap smears. Globally, more than 1.7 billion women over the age of 20 do not undergo any cervical cancer screening.

Question: Mr. Yakatan, please give us a little background on Grant Life Sciences.
Mr. Yakatan: "The technology behind Grant was begun over two years ago when a scientist from China, working with the University of Utah, teamed up with Dr. Mark Rosenfeld to do some work in cervical cancer. As a result of their initial activities they filed a patent for the use of various amino acids to identify the antibodies that surface when a woman has cervical cancer. They looked at blood and body fluids as opposed to the traditional Pap smear. With their patent applied for, they connected with a local entrepreneur named Michael Ahlin, who today is our Vice President of Development and a Director with Grant, and he provided some initial capital. When the venture capital route proved to be too dilutive, they began working with a brokerage firm here in New York to facilitate a reverse merger with a publicly traded entity to raise capital, which was done quickly and successfully. Then I and several others with a lot of experience were recruited to be the management team, which is where we are today."


Question: What is it that your test can do that others can't?
Mr. Yakatan: "Normally to check cervical cancer, women generally go for a Pap smear, which is considered in the industry to be highly inaccurate. Currently, there is no simple test, where you can just take the blood from a patient and determine by measuring antibodies in the blood whether cervical cancer or cervical cancer pre-cursors are present.  We have developed what we believe is the first blood test that does this, and the initial data is extremely compelling."


Question: What is it that your scientists have discovered that hasn't been done before?
Mr. Yakatan: "We've discovered in the literature five or six attempts to identify precursors to cervical cancer through various methods. What our group did is developed a series of oncogenic amino acid sequences.  We have characterized them in a way that can be utilized in a standard screening test where the amino acid sequences would truly identify the presence of cervical cancer or cervical cancer pre-cursors in blood or bodily fluid samples.  I don't think it's any trick or black magic; I think that we've just been able to do a lot of laboratory work in terms of screening hundreds of different amino acid sequences. We have discovered that a test that we would make for the U.S. market may have a different sequence than a test that we would make for the Indian or Chinese markets because the makeup of the oncogenes that show cervical cancer activity vary in different geographical areas of the world. What we are doing now is working very closely with a partner, Allogen, which is a part of the Cleveland Clinic Foundation, in trying to characterize all of these amino acids. We think that within three to six months, we'll be able to have our initial characterization completed and a product essentially ready to go into clinical trials, both in the United States and in other places in the world."


Question: What's the process and about how long does it take?
Mr. Yakatan: "We think that the longest process for us is the amino acid characterization.  What we want to do is a sample collection before we go to any regulatory agency; we then test these samples from thousands of patients in what we call institutional review board programs. We have a few of them already set-up at USC, UCLA, Johns Hopkins and a local hospital in Utah. We've begun an active program to identify 4,000 samples within a six-month period to do the characterization program. So we think it may take two to three months to characterize the amino acids; another four to six months to do the sample collection and process those samples. Then we would begin a regulatory submission. If we are lucky, and I say lucky is the key word, we will be able to file a 510K with the US FDA (Food and Drug Administration) as an adjunct to Pap smears and that process could take three to six months. However, if we have to do a complete product disclosure process, it could take as much as eighteen months to two years. We believe that in the rest of the world we can get a swift approval of our rapid test. We think that once the nine months to a year of laboratory development time and amino acid characterization is completed, we could put a product on the market outside of the U.S. within a year."


Question: Where do you go from here?
Mr. Yakatan: "We're continuing to characterize the amino acid sequences to make sure that we have the right sequences. We are currently developing two products, the first of which is an ELISA (Enzyme Linked Immunosorbent Assay) test which we would file as an adjunct in the United States through the FDA.   The second is a rapid test-- a point-of-care test that would be low cost and could serve the more than 1.7 billion women outside of the United States and Europe who normally don't get any type of cervical screening.  This probably accounts for over half the world and can be due to religious or economic reasons or just some type of taboo where women don't feel comfortable getting a cervical exam from a physician."


Question: Is there a market for rapid test in the United States?
Mr. Yakatan: "The issue is how imbedded the Pap smear is in the U.S. and whether or not we would  be able to get the community to accept a blood test after 50 years of doing traditional Paps. In our early discussions with people in the marketplace as well as the FDA, it's been suggested to us that the best way to get a new cancer test approved is as an adjunct. So, we think that strategically it makes sense to develop an adjunct test for the U.S. market and develop an inexpensive rapid test for the global market."


Question: Do you have enough funding going forward?
Mr. Yakatan: "Our initial capitalization was through a reverse merger were we raised about $1.8 million total. We are now looking for another $3 to $5 million and we think that with that second round of financing, we should be able to complete all of the pre-market activities and get the products on the market."


Question: What is the market potential for your test?
Mr. Yakatan: "In the United States, there are 60 million women who receive routine Paps of some form. Out of that, about 20% get false positives or false negatives, which lead to about 9 million colposcopy procedures; of that, 7 million turn out to be negative. So, we want to focus on an adjunct test where we could reduce the number of colposcopies and save the American health care system over $1.5 billion annually, not to mention eliminating the unnecessary mental anguish some of the false negatives create for our mothers and daughters.  We think that the U.S. market alone is about 7 to 10 million tests annually at $25.00 to $30.00 a test.  As I said before, the world market outside of the U.S. consists of over 1.7 billion women that have never been screened. We think that for those women, we can develop a test that would cost under $5.00, which is our goal. Then, we would ultimately put that same test on the market in the United States. I was retired for many years from being a CEO in biotech and when the opportunity came to me to look at a novel patented technology that serves an unmet market of over 1.7 billion people, that was enough excitement to get me to come back to work again."


Question: Can you give us an idea of what you are up against in the medical community to gain acceptance for your new approach?
Mr. Yakatan: "The issue is that Dr. George Papanicolaou developed this test about 68 years ago.  If you talk to any medical pathologist they will tell you that this is an archaic test that is highly inaccurate. However, it has become well accepted in the community. It is completely reimbursed by the insurance community and if they get a false positive, the patient would then go for a colposcopy, another reimbursable procedure. Unfortunately false negatives are more problematic of course. Just to give an idea of how well entrenched the Pap smear is in the United States, there was a recent article in the N.Y. Times that pointed out that about 12% of the women receiving Pap smears have had hysterectomies. They don't even have a cervix any longer to take a Pap sample from!.  Our new medical director, David Bolick, MD, FCAP, MIAC, is one of the most well-known spokesmen in the world for the replacement of the Pap smear. It's one of the reasons we brought David into our fold and he will be speaking at meetings all around the United States on our technology."


Question: What about going directly to women and women's groups?
Mr. Yakatan: "We plan to do exactly that. One of our founders, Michael Ahlin, has been given the responsibility to look into women's groups around the United States and see if we can generate support. It is common knowledge among the medical community that the current process of the cervical examination a very negative and highly invasive experience."


Question: Could you address potential investors; what should they know about the background of the management and the company that would make them want to invest it Grant Life Sciences?
Mr. Yakatan: "We have a very experienced management team. I have 35 years of experience in the biotech world. There are people who consider me part of the old guard. I've run companies like this before and much of the investment community knows who I am and my track record. We have a CFO, John Wilson, who has a similar background and a strong financial pedigree. He was senior banker at Credit Suisse First Boston and prior to that, served as CFO for Hardee's Food Systems, Perrier USA and Bell Canada International.  John has served on numerous boards, both public and private. In many of these cases, he was their CFO and did tremendous things for them. We have someone who has 20 years experience in product development ready to join us. In diagnostics we are working with the man who actually developed the rapid test program for Hoffmann-La Roche in terms of developing our rapid test program. We are working directly with the cancer center in China and that's important because China has the highest incidence of cervical cancer in the world. There are approximately 100,000 deaths there a year because of the lack of screening and we are the only company that is working directly with the center.  One of our founders, and a continuing consultant to the Company, is a scientific advisor to the center in China and has about ten years experience in the Chinese market. We brought on as a consultant to the company a former high level executive at the National Cancer Institute and he is working with us in terms of government funding and grants.  We believe that within the next 2 to 3 months we will solidify a major relationship with an institute in the United States that has the largest W.H.O. grant in the world for this type of work. So, we think that the combination of the experience of the management team, plus the market size and viability of the market are excellent opportunities for investors."


Question: In closing, could you tell us how long do you anticipate it will take for acceptance?
Mr. Yakatan: "The acceptance will be very rapid. We've actually had discussions with the Gates Foundation and other organizations that specialize in finding funding for third world countries and we are just in the early stages of those discussions. In reality, the company as it exists now is essentially two months old. The management team has worked very closely with the founders to pull together all the work that has been done to date and that has been a harmonious relationship."

thanks & applaud

[eliteG]

both GLIF and DIAAF aren't doing much.  Nothing to talk about other than they still look good.  Its hard to wait around.. looking to see if anything else is happenin.  Sometimes you gotta wait for momentum...

[dhiraj19]

EliteG,

I yesterday bought MZT before earning close. Currently its 0.7, what do you say shall I dump it or  shall I wait to minimize my loss. Appreciated all your help.
( Applaud)
- Dhiraj

[mezz]

action on MOTGE is interesting. volume looks ok to be atleast ave today we'll see

[MarketRonin]

glif looks to be headed to .046 today...

[eliteG]

EliteG,

I yesterday bought MZT before earning close. Currently its 0.7, what do you say shall I dump it or  shall I wait to minimize my loss. Appreciated all your help.
( Applaud)
- Dhiraj

Ouch man  if you wanna wait just make sure you set up a stopping point.. other than that I really cant say Dhiraj  .  What I would do is probably sell it and forget about it    I think I see some bacon(finally) to make up for it.. I'll post it when I'm done with the analysis 

action on MOTGE is interesting. volume looks ok to be atleast ave today we'll see

it does look nice.. wish there was more volume too